Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Clinical trial NCT00363974 · COMPLETED

Trial details

NCT number: NCT00363974
Sponsor: Aegera Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Myelomonocytic, Acute

Start date: 2005-10-01
Primary completion: 2009-03-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.